PATENT CLAIM ANALYSIS

Application Number: 16148601
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["514", "017800"]

Abstract:
The disclosure pertains to methods of treating or preventing a disease or condition associated with and/or induced by soluble A-beta oligomer such as Alzheimer's disease by administering to a subject in need thereof conformation specific and/or selective antibodies or binding fragments thereof and related products.

Claim (Index 3):
The method of  claim 1 , wherein the antibody or binding fragment selectively binds to the cyclic compound cover a corresponding linear peptide and/or selectively binds A-beta oligomer over A-beta monomer and/or A-beta fibril, wherein the antibody is at least 2 fold, 3 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold, at least 100 fold, at least 500 fold, at least 1000 fold more selective for the cyclic compound over the corresponding linear compound.

Metadata:
- Claim Count in Document: 30.0
- Percentile: 97.0
- Lexical Diversity: 1.20513
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['11304986', '14967260', '13701151', '10642099', '14383602']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7914146252492742
- 35 USC 102 Novelty (BERT): 0.5291414327741482
- Combined Prediction Score: 0.7651873060017617
- Mean Citation Score: 329.930246
- Max Citation Score: 341.01526
- Similarity Product: 235.02159360674383

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test